Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Organogenesis Holdings (ORGO) EBIT: 2016-2024

Historic EBIT for Organogenesis Holdings (ORGO) over the last 9 years, with Dec 2024 value amounting to -$1.3 million.

  • Organogenesis Holdings' EBIT rose 232.06% to $20.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.4 million, marking a year-over-year increase of 34.41%. This contributed to the annual value of -$1.3 million for FY2024, which is 110.24% down from last year.
  • According to the latest figures from FY2024, Organogenesis Holdings' EBIT is -$1.3 million, which was down 110.24% from $12.5 million recorded in FY2023.
  • Over the past 5 years, Organogenesis Holdings' EBIT peaked at $72.2 million during FY2021, and registered a low of -$1.3 million during FY2024.
  • Over the past 3 years, Organogenesis Holdings' median EBIT value was $12.5 million (recorded in 2023), while the average stood at $11.2 million.
  • As far as peak fluctuations go, Organogenesis Holdings' EBIT spiked by 189.44% in 2020, and later plummeted by 110.24% in 2024.
  • Over the past 5 years, Organogenesis Holdings' EBIT (Yearly) stood at $26.7 million in 2020, then surged by 170.48% to $72.2 million in 2021, then tumbled by 69.12% to $22.3 million in 2022, then plummeted by 43.84% to $12.5 million in 2023, then slumped by 110.24% to -$1.3 million in 2024.